Longitudinal Monitoring of ctDNA in Patients with Melanoma and Brain Metastases Treated with Immune Checkpoint Inhibitors.

doi:10.1158/1078-0432.CCR-19-3926

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Longitudinal Monitoring of ctDNA in Patients with Melanoma and Brain Metastases Treated with Immune Checkpoint Inhibitors.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Aug 2020

Lee Jenny H, Menzies Alexander M, Carlino Matteo S, McEvoy Ashleigh C, Sandhu Shahneen, Weppler Alison M, Diefenbach Russell J, Dawson Sarah-Jane, Kefford Richard F, Millward Michael J, Al-Ogaili Zeyad, Tra Thien, Gray Elin S, Wong Stephen Q, Scolyer Richard A, Long Georgina V, Rizos Helen

Abstract excerpt

PURPOSE: Brain involvement occurs in the majority of patients with metastatic melanoma. The potential of circulating tumor DNA (ctDNA) for surveillance and monitoring systemic therapy response in patients with melanoma brain metastases merits investigation. EXPERIMENTAL DESIGN: This study examined circulating BRAF, NRAS, and c-KIT mutations in patients with melanoma with active brain metastases receiving PD-1...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Circulating Tumor DNA

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to GTP Phosphohydrolases

Share to Immune Checkpoint Inhibitors

Share to Kaplan-Meier Estimate

Share to Longitudinal Studies

Share to Melanoma

Share to Proto-Oncogene Proteins c-kit

Share to Skin Neoplasms

Source

Open in PubMed

Identifiers

PMID: 32321716
DOI: 10.1158/1078-0432.CCR-19-3926

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Longitudinal Monitoring of ctDNA in Patients with Melanoma and Brain Metastases Treated with Immune Checkpoint Inhibitors.PMID 32321716Read ↗

Circulating Tumor DNA Analysis and Functional Imaging Provide Complementary Approaches for Comprehensive Disease Monitoring in Metastatic MelanomaSemantic proximity Read ↗

The Prognostic Value of BRAF, C-KIT, and NRAS Mutations in Melanoma Patients With Brain Metastases.Semantic proximity Read ↗

Sensitivity of plasma BRAFmutant and NRASmutant cell-free DNA assays to detect metastatic melanoma in patients with low RECIST scores and non-RECIST disease progression.Semantic proximity Read ↗

Dynamic monitoring of cerebrospinal fluid circulating tumor DNA to identify unique genetic profiles of brain metastatic tumors and better predict intracranial tumor responses in non-small cell lung cancer patients with brain metastases: a prospective cohort study (GASTO 1028).Semantic proximity Read ↗

Circulating tumor DNA is a prognostic biomarker in metastatic melanoma patients treated with chemoimmunotherapy and BRAF inhibitor.Semantic proximity Read ↗

Circulating Tumor DNA Is Prognostic of Patient Outcome and Enables Therapy Monitoring in Metastatic Uveal Melanoma.Semantic proximity Read ↗

Unraveling the Enigma of Melanoma Brain Metastasis: New Horizons in Mechanisms, Diagnosis, and TherapySemantic proximity Read ↗

Dynamic ctDNA evaluation of a patient with BRAFV600E metastatic melanoma demonstrates the utility of ctDNA for disease monitoring and tumor clonality analysis.Semantic proximity Read ↗

Circulating Tumor DNA (ctDNA) Clearance After Immune Checkpoint Inhibition (ICI) with Radiotherapy (RT) as a Prognostic Biomarker for Advanced MelanomaSemantic proximity Read ↗

Sequencing of Checkpoint or BRAF/MEK Inhibitors on Brain Metastases in MelanomaSemantic proximity Read ↗

Genetic Characterization of Brain Metastases in the Era of Targeted TherapySemantic proximity Read ↗

From validity to clinical utility: the influence of circulating tumor DNA on melanoma patient management in a real-world setting.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.